Related Experiment Video

Updated: Dec 8, 2025

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

11.9K

Circulating vascular adhesion protein-1(VAP-1): a possible biomarker for liver fibrosis associated with chronic

Zehra Öksüz1, Enver Üçbilek2, Mehmet Sami Serin3

  • 1Department of Pharmaceutical Microbiology, Mersin University Faculty of Pharmacy, Mersin, Turkey. zehraoksz@gmail.com.

Brazilian Journal of Microbiology : [Publication of the Brazilian Society for Microbiology]
|September 22, 2020
PubMed

Insights

Vascular adhesion protein-1 (VAP-1) levels increase with fibrosis severity in chronic hepatitis B patients, suggesting VAP-1 as a biomarker for fibrogenesis. Levels were higher in CHB than CHC patients.

Area of Science:

  • Hepatology
  • Biomarker Discovery
  • Immunology

Background:

  • Vascular adhesion protein-1 (VAP-1) is implicated in chronic liver diseases and fibrogenesis.
  • Understanding VAP-1's role in disease progression is crucial for developing noninvasive diagnostic tools.

Purpose of the Study:

  • To investigate the association between VAP-1 levels and the severity of fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) and C (CHC) patients.
  • To evaluate VAP-1 as a potential noninvasive biomarker for monitoring liver disease progression.

Main Methods:

  • Serum VAP-1 concentrations were measured using ELISA in CHB and CHC patients across different fibrosis stages (F0-F4), cirrhosis, and HCC.
  • VAP-1 levels were compared between fibrosis stages and disease types.

Main Results:

  • VAP-1 levels significantly increased with fibrosis progression in CHB patients, peaking at stage F4 (severe fibrosis).
  • A significant difference in VAP-1 was observed between F0 and F4 in CHB, but not between F1 and F4 in CHC.
  • No significant difference in VAP-1 levels was found between cirrhosis and HCC patients for either CHB or CHC.
  • VAP-1 levels were generally higher in CHB than in CHC patients.

Conclusions:

  • VAP-1 levels may serve as a noninvasive biomarker for assessing fibrogenesis severity in chronic hepatitis B infection.
  • Further research is warranted to explore VAP-1's utility in CHC and its correlation with other liver disease markers.

Keywords:
BiomarkerChronic hepatitis BChronic hepatitis CFibrosisVascular adhesion protein-1 (VAP-1)

More Related Videos

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

54.0K
A Flow Adhesion Assay to Study Leucocyte Recruitment to Human Hepatic Sinusoidal Endothelium Under Conditions of Shear Stress11:38

A Flow Adhesion Assay to Study Leucocyte Recruitment to Human Hepatic Sinusoidal Endothelium Under Conditions of Shear Stress

Published on: March 21, 2014

15.7K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
101
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
126
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
399
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
373